Jpmorgan Chase & Co »

Arrivent Biopharma shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Arrivent Biopharma (AVBP) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-06-30 $82k 4.4k 18.55
2024-03-31 $224k 13k 17.86

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf (SPY)
Meta Platforms Common (META)
Alphabet Common (GOOG)
Eli Lilly & Co Common (LLY)
Unitedhealth Group Common (UNH)
Mastercard Incorporated Common (MA)
Broadcom Common (AVGO)
Alphabet Common (GOOGL)
Vanguard Total Intl Bond Etf Fund (BNDX)
Vanguard S&p 500 Etf idx (VOO)
Ishares Core S&p 500 Etf Fund (IVV)

View all positions for Jpmorgan Chase & Co

Top funds holding Arrivent Biopharma

Hillhouse Capital Advisors
OrbiMed Advisors
Octagon Capital Advisors
Suvretta Capital Management
Sofinnova Ventures
Novo A/S
Sc China Holding
BlackRock
Vanguard Group
Cormorant Asset Management
Perceptive Advisors
Geode Capital Management
State Street Corporation
Woodline Partners
Charles Schwab Investment Management

View all funds holding Arrivent Biopharma